Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1814 • ACR Convergence 2021
Patient Characteristics and Clinical Features Associate with Health-Related Quality of Life in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
Jeffrey Curtis¹, Iain McInnes², Proton Rahman³, Dafna Gladman⁴, Feifei Yang⁵, Steven Peterson⁶, Prasheen Agarwal⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Chenglong Han⁹, May Shawi¹⁰, William Tillett¹¹ and Philip Mease¹², ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ⁷Department of Biostatics, Janssen Research & Development, LLC, Spring House, Spring House, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis, & skin/nail psoriasis. Patients (pts) with PsA often experience reduced…
Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Marijn Vis¹, Pascal Richette², Ramirez Julio³, Marlies Neuhold⁴, Robert Wapenaar⁵, Elke Theander⁶, Wim Noel⁷, May Shawi⁸, Alexa Kollmeier⁹ and William Tillett¹⁰, ¹Erasmus MC, Badhoevedorp, Netherlands, ²Lariboisiere Hospital, Paris, France, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Janssen-Cilag, Zug, Switzerland, ⁵Janssen-Cilag BV, Breda, Netherlands, ⁶Janssen Cilag, Lund, Sweden, ⁷Janssen Pharmaceutica, Vilvoorde, Belgium, ⁸Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
Abstract Number: 0054 • ACR Convergence 2021
TCR Immune Profiling of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: CD8+ and CD4+ T cell subsets have been implicated in the pathogenesis of psoriatic disease. Here, we explore the T-cell repertoire in psoriatic disease…
Abstract Number: 0234 • ACR Convergence 2021
Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Louis Bessette¹, Beatriz Joven-Ibáñez², Carlo Selmi³, Naijun Chen⁴, Koji Kato⁵, Ralph Lippe⁶, Patrick Zueger⁷, Jayeshkumar Patel⁴ and Joseph Merola⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ²University Hospital 12 de Octubre, Madrid, Spain, ³Humanitas Research Hospital and Humanitas University, Milan, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁷AbbVie Inc., Mettawa, IL, ⁸Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is…
Abstract Number: 0748 • ACR Convergence 2021
Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
Xenofon Baraliakos, Styliani Tsiami, Maria Claudia Gkelaki, Piet Dukatz, Uta Kiltz and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…
Abstract Number: 1162 • ACR Convergence 2021
Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
Jackie Tsang¹, Orli Silverberg¹, Rohan Machhar², Remy Pollock³, Mitchell Sutton⁴, Daniel Pereira³, Dafna Gladman⁵ and Cheryl Rosen¹, ¹University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: We aimed to assess the correlation between cannabis use and psoriatic disease severity, health-related quality of life, pain, and psychosocial outcomes in psoriasis without…
Abstract Number: 1330 • ACR Convergence 2021
Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Philip Mease¹, Philip S Helliwell², Dafna Gladman³, Denis Poddubnyy⁴, Xenofon Baraliakos⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Xie Xu⁸, Shihong Sheng⁸, Stephen Xu⁸, May Shawi⁹, Désirée van der Heijde¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a selective IL-23p19 inhibitor, resulted in greater mean improvements in BASDAI scores vs placebo (PBO) at W24 among patients (pts) with active…
Abstract Number: 1347 • ACR Convergence 2021
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
Atul Deodhar¹, Dafna Gladman², Rebecca Bolce³, David Sandoval³, So Young Park³, Soyi Liu-Leage⁴, Peter Nash⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Neuilly sur Seine, France, ⁵Griffith University, Brisbane, Australia, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…
Abstract Number: 1363 • ACR Convergence 2021
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA
Pascal Richette¹, Marijn Vis², Sarah Ohrndorf³, William Tillett⁴, Marlies Neuhold⁵, Michel van Speybroeck⁶, Elke Theander⁷, Wim Noel⁸, May Shawi⁹, Alexa Kollmeier¹⁰ and Alen Zabotti¹¹, ¹Lariboisiere Hospital, Paris, France, ²Erasmus MC, Badhoevedorp, Netherlands, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Janssen-Cilag, Zug, Switzerland, ⁶Janssen Pharmaceutica, Belgium, Belgium, ⁷Janssen Cilag, Lund, Sweden, ⁸Janssen Pharmaceutica, Vilvoorde, Belgium, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Janssen Research & Development, LLC, La Jolla, CA, ¹¹University of Udine, Udine, Italy
Background/Purpose: Psoriatic arthritis (PsA) is mainly described based on the individual domains or clinical components of the disease.1,2 The aim of this post hoc analysis…
Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Megan Meier¹, Jessica Walsh² and Shaobo Pei³, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Shashank Cheemalavagu¹, Yuxuan Jin² and Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…
Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Thierry Sornasse¹, Jaclyn Anderson², Koji Kato³, Apinya Lertratanakul⁴, Christopher Ritchlin⁵ and Iain McInnes⁶, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc, Gurnee, IL, ³AbbVie Inc, Shinagawa- Ku, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…
Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Joseph Merola¹, Iain McInnes², Atul Deodhar³, Erhard Quebe-Fehling⁴, Maher Aassi⁴, Michael Peine⁴ and Nehal Mehta⁵, ¹Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
Abstract Number: 0056 • ACR Convergence 2021
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
Lihi Eder¹, Darshini Ganatra² and Vinod Chandran³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity in immune cell populations among patients with psoriatic arthritis (PsA) may determine disease expression and treatment response. The objective of this study was…
Abstract Number: 0239 • ACR Convergence 2021
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Elaine Husni¹, Steven Peterson², Natalie Dennis³, Feifei Yang⁴, Iris Lin⁴, Yiting Wang⁵, Soumya Chakravarty⁶, Claire Fischer³, May Shawi⁷, Arthur Quenéchdu³ and Joseph Merola⁸, ¹Cleveland Clinic, Cleveland, OH, ²Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].